SCHEDULE 13D/A: Lipella Pharmaceuticals Insider Michael Chancellor Updates Beneficial Ownership to 7.9%
Schedule 13D Amendment
Dr. Michael B. Chancellor, Chief Medical Officer and a Director of Lipella Pharmaceuticals Inc., has updated his beneficial ownership stake to 7.9% of the company's common stock.
Summary
- Dr. Michael B. Chancellor, the Chief Medical Officer and a member of the Board of Directors of Lipella Pharmaceuticals Inc., has filed an Amendment No. 8 to his Schedule 13D.
- This amendment updates his beneficial ownership percentage in Lipella Pharmaceuticals Inc. to 7.9% of the common stock.
- Dr. Chancellor beneficially owns an aggregate of 209,640 shares of common stock.
- This total includes 109,703 shares purchased with personal funds and 99,937 shares issuable upon the exercise of fully vested stock options.
- The beneficial ownership percentage is calculated based on 2,548,811 shares of Common Stock outstanding as of the date of this Amendment No. 8.
- The Reporting Person has not engaged in any transactions with respect to the Common Stock of the Issuer during the sixty days prior to the filing date of this Amendment No. 8.
Sentiment
Score: 6
Explanation: The sentiment is mildly positive due to the continued significant insider ownership, part of which was personally funded, suggesting confidence. However, it's largely neutral as it's a factual, routine disclosure without new operational or financial performance details.
Positives
- A key insider, Dr. Michael B. Chancellor (CMO and Director), maintains a significant beneficial ownership stake of 7.9% in the company, indicating continued alignment with shareholder interests.
- A portion of Dr. Chancellor's ownership (109,703 shares) was acquired through personal funds, which can be viewed as a sign of confidence in the company's future.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This filing is a routine disclosure of insider ownership, common across all publicly traded companies. It does not provide specific insights into broader industry trends or competitive landscape, but rather focuses on a single insider's stake in Lipella Pharmaceuticals Inc.
Stakeholder Impact
- Shareholders: Provides transparency regarding the ownership stake of a key executive and director, which can influence investor confidence.
- Employees: No direct impact mentioned.
- Customers: No direct impact mentioned.
- Suppliers: No direct impact mentioned.
- Creditors: No direct impact mentioned.
Key Dates
| Date | Description |
|---|---|
| 2022-12-29 | Initial Statement on Schedule 13D filed by the Reporting Person. |
| 2023-06-21 | Amendment No. 1 to Schedule 13D filed. |
| 2024-03-06 | Amendment No. 2 to Schedule 13D filed. |
| 2024-03-15 | Amendment No. 3 to Schedule 13D filed. |
| 2024-08-19 | Amendment No. 4 to Schedule 13D filed. |
| 2024-10-17 | Amendment No. 5 to Schedule 13D filed. |
| 2025-01-23 | Amendment No. 6 to Schedule 13D filed. |
| 2025-01-30 | Amendment No. 7 to Schedule 13D filed. |
| 2025-02-06 | Date of event which requires filing of this statement (reference date for ownership calculation). |
| 2025-02-10 | Date of filing of Amendment No. 8 to Schedule 13D. |
Keywords
Lipella Pharmaceuticals, Michael B. Chancellor, Schedule 13D, Beneficial Ownership, Insider Ownership, Common Stock, SEC Filing, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.